RxDoctor Payments Data

Heather Berry, NP

Nurse Practitioner · Franklin, VANPI 1417656612

Payments from drug & device makers

$1,110in general payments, 2019–2025

Across 47 payments — averaging $23.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$356
  • Scpharmaceuticals Inc.$228
  • Boston Scientific$125
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$105
  • Alnylam Pharmaceuticals Inc.$60
  • Amgen$42
  • plus $194 from 8 others

What the payments were for

  • Food & beverage$1,110100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,110 in reported general payments places this provider in the 80th percentile of 2,166 nurse practitioner providers in Virginia.

See all nurse practitioner providers in Virginia

Medicare billing

Part B allowed, 2024
$57,509
Medicare patients
258
Services billed
672

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban199$206,365
EntrestoSacubitril/Valsartan105$127,472
JardianceEmpagliflozin63$64,040
XareltoRivaroxaban48$51,722
FarxigaDapagliflozin Propanediol28$35,447
BrilintaTicagrelor19$20,113
Ranolazine ErRanolazine104$5,199
VascepaIcosapent Ethyl12$4,140
Metoprolol Succinate247$2,320
Atorvastatin Calcium241$2,078
Rosuvastatin Calcium129$1,787
Ezetimibe67$1,753
Bumetanide46$1,204
Valsartan58$1,198
Carvedilol143$1,100

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$356$127,472105 claims
Boehringer IngelheimJardiance$20$64,04063 claims
AstraZenecaFarxiga, Brilinta$39$55,56047 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,166 nurse practitioner providers in Virginia.

Other nurse practitioner in Franklin

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →